Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data from its infectious disease portfolio at the IDWeek 2025 congress, scheduled to take place in Atlanta from October 19–22, 2025. The company will feature 46 abstracts from both Pfizer- and collaborator-led studies, highlighting significant advancements in the prevention and treatment of infectious diseases.
"IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoing battle against infectious diseases," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer.
"At Pfizer, we continue to prioritize innovation and rigorous data generation through clinical studies and real-world analysis supporting the vaccines and therapeutics for our infectious disease pipeline."
The presentations will cover research across Pfizer’s broad infectious disease portfolio, including COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, and other serious bacterial and viral infections.
Also Read